IL-1 alpha

IL-1 alpha Overview

English NameInterleukin-1 alphaApproved Drugs1
Drugs in Clinical Trials11Target SynonymInterleukin-1 Alpha,IL1A,IL1F1,IL-1 alpha,Interleukin 1 Alpha,Hematopoietin-1,Pro-Interleukin-1-Alpha,Preinterleukin 1 Alpha,IL1-ALPHA,IL-1A,IL1,Interleukin-1alpha
Highest Development StageApproved
English NameInterleukin-1 alpha
Target SynonymInterleukin-1 Alpha,IL1A,IL1F1,IL-1 alpha,Interleukin 1 Alpha,Hematopoietin-1,Pro-Interleukin-1-Alpha,Preinterleukin 1 Alpha,IL1-ALPHA,IL-1A,IL1,Interleukin-1alpha
Approved Drugs1
Drugs in Clinical Trials11
Highest Development StageApproved

IL-1 alpha Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (2)Mouse (2)

  • Tag

    His Tag (2)His Tag & Avi Tag (2)

  • Conjugate

    Unconjugated (2)Biotin-labeled (2)

IL-1 alpha Background

Interleukin-1 alpha (IL1a) is also known as IL-1A, IL1, IL1-ALPHA,IL1F1,and is a cytokine of the interleukin-1 family. IL1a possesses a wide spectrum of metabolic, physiological, haematopoietic activities, and plays one of the central roles in the regulation of the immune responses. It binds to the interleukin-1 receptor. IL-1α is constitutively produced by epithelial cells. It is found in substantial amounts in normal human epidermis and is distributed in a 1:1 ratio between living epidermal cells and stratum corneum.The constitutive production of large amounts of IL-1α precursor by healthy epidermal keratinocytes interfere with the important role of IL-1α in immune responses, assuming skin as a barrier, which prevents the entry of pathogenic microorganisms into the body. In vitro, IL-1α possesses biological effect on cells in the picomolar to femtomolar range. In vivo, Shortly after an onset of an infection into organism, IL-1α activates a set of immune system response processes.

IL-1 alpha Synonyms

IL1A,IL-1 ALPHA,IL1F1,IL1α

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Tadekinig alfar-hIL-18BP; IL-18BPPhase 3 ClinicalAb2 Bio LtdAutoimmune Lymphoproliferative Syndrome; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome
Details
LutikizumabABT-981Phase 3 ClinicalAbbvie IncColitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Hidradenitis Suppurativa; Osteoarthritis; Osteoarthritis, Knee
Details
KPL-387KPL-387Phase 3 ClinicalKiniksa Pharmaceuticals LtdHeart Diseases; Pericarditis
Details
BermekimabT2-18C3; RA-18C3; CV-18C3; CA-18C3; MABP-1; MABp1; JNJ-77474462; MAB-p1Phase 2 ClinicalXbiotech IncAcne Vulgaris; Colorectal Neoplasms; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Digestive System Diseases; Eczema; Hematologic Neoplasms; Hidradenitis Suppurativa; Neoplasms; Psoriasis; Pyoderma Gangrenosum; Scleroderma, Systemic
Details
ABBV-9832ABBV-9832Phase 2 ClinicalAbbvie IncArthritis, Rheumatoid
Details
ABBV-166ABBV-166Phase 2 ClinicalAbbvie IncArthritis, Psoriatic; Crohn Disease
Details
AC-701AC-701Phase 2 ClinicalTwi Pharmaceuticals IncExanthema; Rosacea
Details
VilamakitugXB-2001Phase 2 ClinicalXbiotech IncArthritis, Rheumatoid; Axial Spondyloarthritis; Pancreatic Neoplasms; Rheumatic Diseases
Details
CAN-10CAN-10Phase 1 ClinicalLund University FoundationMyocarditis; Plaque psoriasis; Scleroderma, Systemic
Details
GenSci-161GenSci-161Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co LtdEndometriosis; Hidradenitis Suppurativa
Details
Interleukin-1-alpha targeting antibody (XBiotech)Phase 1 ClinicalXbiotech Inc
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
RilonaceptKPL-914; RGN-303ApprovedRegeneron Pharmaceuticals IncArcalyst, 炎朵United StatesCryopyrin-Associated Periodic SyndromesKiniksa Pharmaceuticals Ltd2008-02-27Anemia; Arthritis, Juvenile; Atherosclerosis; Coronary Artery Disease; Cryopyrin-Associated Periodic Syndromes; Deficiency of interleukin-1 receptor antagonist; Diabetes Mellitus, Type 1; Familial Mediterranean Fever; Genetic Diseases, Inborn; Gout; Hearing Loss, Sensorineural; Inflammation; Muckle-Wells Syndrome (MWS); Pericarditis; Renal Insufficiency, Chronic; Sarcoidosis; Schnitzler Syndrome; Scleroderma, Diffuse; Scleroderma, Systemic; Still's Disease, Adult-Onset; Urticaria; Vascular Diseases
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information